| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
B. Riley Securities analyst Mayank Mamtani reiterates Novavax (NASDAQ:NVAX) with a Buy and lowers the price target from $18 ...
After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading...
Novavax (NASDAQ:NVAX) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(1.19) by 59...
Novavax (NASDAQ:NVAX) raises FY2025 sales outlook from $1.000 billion-$1.050 billion to $1.040 billion-$1.060 billion vs $1.051...
Novavax (NASDAQ:NVAX) reported quarterly losses of $(1.25) per share which beat the analyst consensus estimate of $(1.33) by 6....
TD Cowen analyst Brendan Smith maintains Novavax (NASDAQ:NVAX) with a Hold and lowers the price target from $8 to $7.
SEC